{
    "DATE": " 3-MAR-1987 17:54:29.53",
    "TOPICS": [
        "earn"
    ],
    "PLACES": [
        "usa"
    ],
    "NEWID": "1391",
    "TEXT": {
        "TITLE": "ZENITH LABS <ZEN> WILL REPORT 4TH QTR LOSS",
        "DATELINE": "    RAMSEY, N.J., March 3 - ",
        "BODY": "Zenith Laboratories Inc said the\ncompany will report a fourth quarter loss, and the amount will\nbe determined on completion of its year end audit. The company\ndid not elaborate further.\n    For the third quarter ended Sept 30, 1986, Zenith reported\na loss of 3,451,000 dlrs or 16 cts per share, adjusted for a\nMay 1986 2-for-1 stock split.\n    The company also said it received Food and Drug\nAdministration approval to market Cefadroxil, a generic version\nof an antibiotic with domestic sales exceeding 50 mln dlrs in\n1986.\n    Zenith said it will not market the drug until \"questions\nrelating to the applicability of certain patents have been\nresolved.\"\n Reuter\n\u0003"
    },
    "ORGS": [
        "ec"
    ]
}